An anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs. The first to be approved was muromonab-CD3 in 1986, to treat …

Jun 9, 2019 · We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor–nonbinding anti-CD3 monoclonal antibody) involving relatives of …

Treatment of T cells with monoclonal anti-CD3 antibodies and anti-CD28 antibodies provide a co-stimulatory signal that engages the TCR which can be used for antigen-induced activation. …

Antibodies that detect CD3 can be used in several scientific applications, including Flow Cytometry, Immunohistochemistry, Western Blot, Immunocytochemistry and …

Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to …

Jul 20, 2007 · At variance with presently available therapies for autoimmunity and transplantation, CD3-specific monoclonal antibodies afford long-term effects following a short administration — …

Jun 17, 2021 · This would explain the relative selectivity of anti-CD3 therapy for diabetogenic T cells while leaving the rest of the immune response intact.

In this review, we summarize the basis of CD3–TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3–TCR function for potentiating …

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at …

Our results suggest that anti-CD3 mAbs were a potential therapy for improving AUC of C-peptide and insulin use in type 1 diabetes.